Neurodegenerative diseases (NDs) such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD) are devastating conditions that can develop without noticeable symptoms, causing irreversible damage to neurons before any signs become clinically evident. NDs are a major cause of disability and mortality worldwide. Currently, there are no cures or treatments to halt their progression. Therefore, the development of early detection methods is urgently needed to delay neuronal loss as soon as possible. Despite advancements in Medtech, the early diagnosis of NDs remains a challenge at the intersection of medical, IT, and regulatory fields. Thus, this review explores “digital biomarkers” (tools designed for remote neurocognitive data collection and AI analysis) as a potential solution. The review summarizes that recent studies combining AI with digital biomarkers suggest the possibility of identifying pre-symptomatic indicators of NDs. For instance, research utilizing convolutional neural networks for eye tracking has achieved significant diagnostic accuracies. ROC-AUC scores reached up to 0.88, indicating high model performance in differentiating between PD patients and healthy controls. Similarly, advancements in facial expression analysis through tools have demonstrated significant potential in detecting emotional changes in ND patients, with some models reaching an accuracy of 0.89 and a precision of 0.85. This review follows a structured approach to article selection, starting with a comprehensive database search and culminating in a rigorous quality assessment and meaning for NDs of the different methods. The process is visualized in 10 tables with 54 parameters describing different approaches and their consequences for understanding various mechanisms in ND changes. However, these methods also face challenges related to data accuracy and privacy concerns. To address these issues, this review proposes strategies that emphasize the need for rigorous validation and rapid integration into clinical practice. Such integration could transform ND diagnostics, making early detection tools more cost-effective and globally accessible. In conclusion, this review underscores the urgent need to incorporate validated digital health tools into mainstream medical practice. This integration could indicate a new era in the early diagnosis of neurodegenerative diseases, potentially altering the trajectory of these conditions for millions worldwide. Thus, by highlighting specific and statistically significant findings, this review demonstrates the current progress in this field and the potential impact of these advancements on the global management of NDs.

Humans are a vision-dominated species; what we perceive depends on where we look. Therefore, eye movements (EMs) are essential to our interactions with the environment, and experimental findings show EMs are affected in neurodegenerative disorders (ND). This could be a reason for some cognitive and movement disorders in ND. Therefore, we aim to establish whether changes in EM-evoked responses can tell us about the progression of ND, such as Alzheimer’s (AD) and Parkinson’s diseases (PD), in different stages. In the present review, we have analyzed the results of psychological, neurological, and EM (saccades, antisaccades, pursuit) tests to predict disease progression with machine learning (ML) methods. Thanks to ML algorithms, from the high-dimensional parameter space, we were able to find significant EM changes related to ND symptoms that gave us insights into ND mechanisms. The predictive algorithms described use various approaches, including granular computing, Naive Bayes, Decision Trees/Tables, logistic regression, C-/Linear SVC, KNC, and Random Forest. We demonstrated that EM is a robust biomarker for assessing symptom progression in PD and AD. There are navigation problems in 3D space in both diseases. Consequently, we investigated EM experiments in the virtual space and how they may help find neurodegeneration-related brain changes, e.g., related to place or/and orientation problems. In conclusion, EM parameters with clinical symptoms are powerful precision instruments that, in addition to their potential for predictions of ND progression with the help of ML, could be used to indicate the different preclinical stages of both diseases.

Neurodegenerative diseases (NDs), including Parkinson’s and Alzheimer’s disease, pose a significant challenge to global health, and early detection tools are crucial for effective intervention. The adaptation of online screening forms and machine learning methods can lead to better and wider diagnosis, potentially altering the progression of NDs. Therefore, this study examines the diagnostic efficiency of machine learning models using Montreal Cognitive Assessment test results (MoCA) to classify scores of people with Parkinson’s disease (PD) and healthy subjects. For data analysis, we implemented both rule-based modeling using rough set theory (RST) and classic machine learning (ML) techniques such as logistic regression, support vector machines, and random forests. Importantly, the diagnostic accuracy of the best performing model (RST) increased from 80.0% to 93.4% and diagnostic specificity increased from 57.2% to 93.4% when the MoCA score was combined with temporal metrics such as IRT—instrumental reaction time and TTS—submission time. This highlights that online platforms are able to detect subtle signs of bradykinesia (a hallmark symptom of Parkinson’s disease) and use this as a biomarker to provide more precise and specific diagnosis. Despite the constrained number of participants (15 Parkinson’s disease patients and 16 healthy controls), the results suggest that incorporating time-based metrics into cognitive screening algorithms may significantly improve their diagnostic capabilities. Therefore, these findings recommend the inclusion of temporal dynamics in MoCA assessments, which may potentially improve the early detection of NDs.

Neurodegenerative diseases (NDs), such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), are debilitating conditions that affect millions worldwide, and the number of cases is expected to rise significantly in the coming years. Because early detection is crucial for effective intervention strategies, this study investigates whether the structural analysis of selected brain regions, including volumes and their spatial relationships obtained from regular T1-weighted MRI scans (N = 168, PPMI database), can model stages of PD using standard machine learning (ML) techniques. Thus, diverse ML models, including Logistic Regression, Random Forest, Support Vector Classifier, and Rough Sets, were trained and evaluated. Models used volumes, Euclidean, and Cosine distances of subcortical brain structures relative to the thalamus to differentiate among control (HC), prodromal (PR), and PD groups. Based on three separate experiments, the Logistic Regression approach was optimal, providing low feature complexity and strong predictive performance (accuracy: 85%, precision: 88%, recall: 85%) in PD-stage recognition. Using interpretable metrics, such as the volume- and centroid-based spatial distances, models achieved high diagnostic accuracy, presenting a promising framework for early-stage PD identification based on MRI scans.